Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema

NCT03397264 is registered in ClinicalTrials.gov with Opthea Limited as lead sponsor.

NCT NCT03397264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03397264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema
Lead sponsor
Opthea Limited
Phase
Phase 1/2
Overall status
Completed
Start date
January 16, 2018
Completion date
June 11, 2020
Enrollment
153 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema